Evoke Pharma, Inc. (EVOK)
| Market Cap | 92.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.31M |
| Shares Out | 26.15M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $2.95 |
| Previous Close | $3.11 |
| Change ($) | -0.16 |
| Change (%) | -5.14% |
| Day's Open | 3.19 |
| Day's Range | 2.90 - 3.19 |
| Day's Volume | 405,448 |
| 52-Week Range | 0.79 - 6.06 |
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and dise...
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and dise...
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and dise...
Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly-launched product Healthcare practitioner survey indicates physicians' awareness and intent to presc...
Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.
Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis Product launch provides healthcare pr...
SOLANA BEACH, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Gimoti commercial launch on track for the fourth quarter of 2020 Gimoti commercial launch on track for the fourth quarter of 2020
Preparing for commercial launch of GIMOTI™ in 4Q 2020 Preparing for commercial launch of GIMOTI™ in 4Q 2020
Preparing commercial launch of GIMOTI™ in 4Q 2020 Preparing commercial launch of GIMOTI™ in 4Q 2020
Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020 Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020
Cheap stocks are effectively Wall Street's casino.
Evoke Pharma received a nod of approval from the U.S. Food and Drug Administration, and investors can now have confidence in EVOK stock.
Last Friday was my 56th consecutive green day of trading and I ended up ending it with a gross profit of $225,000, which easily blows past the $1 million mark for the streak and is several mag...
In an update provided over the weekend, Evoke Pharma Inc. (NASDAQ: EVOK) said that the U.S.
The binary event that was scheduled for last week panned out in favor of Evoke Pharma Inc (NASDAQ: EVOK).
Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021
SOLANA BEACH, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today a...
Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020
SOLANA BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...
EVERSANA to commercialize and distribute Gimoti in the U.S.
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
PDUFA Target Goal Date is June 19, 2020 PDUFA Target Goal Date is June 19, 2020
SOLANA BEACH, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...
SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...
SOLANA BEACH, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today ...
SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma, Inc. (NASDAQ: EVOK) shares have lost about 51% of their value year to date compared to the 9.4%-gain in the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) and a steeper 20% jum...
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
About EVOK
Evoke Pharma, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Sep 25, 2013 |
| CEO David Gonyer | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol EVOK |
Analyst Forecasts
According to 2 analysts, the average rating for Evoke Pharma stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 222.03% from the latest price.